Italy has abolished a decade-old mechanism that allowed pharmaceutical firms to avoid mandatory price reductions, signalling a more rigid approach to public healthcare expenditure and impacting international reference prices
The Scottish Medicines Consortium has modernised the standard contractual terms for pricing agreements, clarifying the legal obligations for health boards and suppliers across NHS Scotland.
New legislative measures in Italy have introduced structural price reductions for reimbursed medicines and established stricter renegotiation protocols for biological products.
A fundamental restructuring of Italy's market access framework will require pharmaceutical companies to adopt a unified clinical and economic approach to secure medicine pricing
The national drug regulator has introduced new standardised guidance to facilitate early scientific dialogue and accelerate patient access to breakthrough therapies.
A major update to the national assessor’s core manual formalises a new era of collaborative regulation, aiming to bring innovative therapies to the NHS up to six months faster.
The newly adopted 2026 budget framework implements significant price cuts for innovative and generic medicines as part of a broader healthcare sustainability strategy.
Pharmaceutical manufacturers in Italy are facing a more intricate year-end financial reconciliation as the national regulator integrates a new rebate mechanism into the standard retail payback cycle.
A sharp reduction in the 2026 repayment rate for branded medicines marks a turning point for the UK’s voluntary pricing agreement, easing the financial burden on developers of innovative therapies.
The UK government and the National Institute for Health and Care Excellence (NICE) have announced the first increase in the institute’s baseline cost-effectiveness thresholds in over 25 years.
Pharmaceutical companies in Italy must now verify their medicine sales records to ensure the accurate calculation of the retail pharmacy payback for the first half of 2025.
A joint ministerial evaluation has found that while France's streamlined drug access schemes have successfully accelerated patient treatment, rising costs necessitate more robust financial regulation.
The French National Authority for Health has launched a public consultation on a draft doctrine regarding the assessment of medicines where clinical evidence is still maturing.
A new proposal by Germany’s health quality institute suggests pharmaceutical companies should pay a 1 per cent turnover tax to sustain the nation’s medical register infrastructure.
German health bodies have agreed to new framework rules that shield physicians from financial penalties when prescribing innovative therapies and biosimilars.
Germany’s federal health committee G-BA has updated its procedural framework to refine how market exclusivity and patient data impact the assessment of innovative drugs.
